Enter your login e-mail to the account
Search
Search parameters
Search results
- Systemic lupus erythematosus – an overview of new knowledge in pathogenesis, clinical picture and treatment
doc. Ing. Stanislava Blažíčková, PhD., prof. MUDr. Jozef Rovenský, DrSc., FRPC, MUDr. Ivana Stiborová
(2/2012, Review articles )
- New drugs era in treating multiple sclerosis
MUDr. Marta Vachová
(5/2009, Review articles ) - Ocrelizumab – clinical evaluation and disease progression – 6,5 years data
MUDr. Eva Recmanová
(5/2021, Review articles ) - Safety monitoring of escalation treatment of multiple sclerosis
MUDr. Jiří Piťha
(5/2019, Review articles ) - Experience with shortened ocrelizumab infusion – ENSEMBLE PLUS study
doc. MUDr. Yvonne Benešová, Ph.D.
(1/2022, Review articles ) - Anti CD20 multiple sclerosis therapy
Doc. MUDr. Pavel Štourač, Ph.D.
(1/2018, Pharmacotherapy ) - Early highefficacy mulitple sclerosis treatment: therapeutic success despite safety barriers
MUDr. Dominika Šťastná, Ph.D., prof. MUDr. Manuela Vaněčková, Ph.D., doc. MUDr. Dana Horáková, Ph.D.
(6/2023, Case reports ) - Efficacy and safety of ocrelizumab in multiple sclerosis
MUDr. Radek Ampapa
(5/2017, Review articles ) - Long term efficacy of ocrelizumab on MRI parameters in multiple sclerosis patients
MUDr. Pavel Hradílek, Ph.D.
(1/2020, Review articles ) - The use of monoclonal antibodies in neurology
prof. MUDr. Egon Kurča, PhD., MUDr. Mária Cuninková
(6/2011, Main topic ) - Ocrelizumab since the first multiple sclerosis attack – a milestone in reimbursement criteria
MUDr. Dominika Šťastná, MUDr. Ingrid Menkyová, doc. MUDr. Dana Horáková, Ph.D.
(4/2022, Review articles ) - Immunological outlook on modern therapy of multiple sclerosis
doc. MUDr. Vojtěch Thon, Ph.D.
(5/2016, From the boundary of neurology ) - Improved cognitive function and employment in patients with relapsing multiple sclerosis treated with ocrelizumab
MUDr. Marek Peterka
(4/2023, Review articles ) - Safety aspects of treating relapsing-remitting multiple sclerosis
MUDr. Radek Ampapa, MUDr. Stanislav Kopecký
(5/2016, Review articles ) - Adherence to treatment in multiple sclerosis: case reports of three female patients on high-efficacy therapy with ocrelizumab
MUDr. Jana Pavlíčková, Ph.D.
(3/2024, Case reports ) - The role of B lymphocytes in the immunopathogenesis and treatment of multiple sclerosis
prof. MUDr. Ľubomír Lisý, DrSc.
(3/2024, Informations ) - Ocrelizumab – pharmacoloical profile
doc. MUDr. Radomír Taláb, CSc., MUDr. Marika Talábová
(5/2018, Pharmacotherapy ) - NEDA-4 concept as a treatment outcome in multiple sclerosis patients
MUDr. Pavel Hradílek, Ph.D.
(3/2016, Review articles ) - Monoklonální protilátky v léčbě roztroušené sklerózy
MUDr. Marek Peterka , MUDr. Zdeněk Kasl, Ph.D.
(2/2018, Pharmacotherapy ) - Biological therapy by Ocrelizumab (antiCD20) is surprisingly clinically effective in multiple sclerosis patients
Prof. RNDr. Jan Krejsek, CSc.
(6/2017, From the boundary of neurology ) - Long-term data of multiple sclerosis treatment with ocrelizumab – eficacy, safety and clinical experience
MUDr. Mgr. Matouš Rous, MUDr. Zuzana Rous, Ph.D.
(6/2021, Review articles ) - Treatment of multiple sclerosis in Czech Republic – options and reality
MUDr. Michal Dufek
(1/2014, Review articles ) - Ocrelizumab – what we know, what we can improve now, what we can improve in the future
MUDr. Martin Elišák, Ph.D.
(1/2024, Review articles ) - Treatment persistence to ocrelizumab and local experience
MUDr. Simona Halúsková, prof. MUDr. Martin Vališ, Ph.D., FEAN
(3/2021, Review articles ) - Ocrelizumab is dampening the harm inflammation in patients with multiple sclerosis with little impact on protective immunity
prof. RNDr. Jan Krejsek, CSc.
(3/2020, From the boundary of neurology ) - B lymfocyty v roztroušené skleróze mozkomíšní a postavení biologika cílícího na B lymfocyty v její léčbě
prof. RNDr. Jan Krejsek, CSc.
(3/2018, From the boundary of neurology ) - Ocrelizumab – long-term efficacy and safety in real-world clinical practice in patients with relapsingremitting multiple sclerosis
MUDr. Martin Elišák, Ph.D.
(3/2022, Review articles ) - New perspective treatment of multiple sclerosis
doc. MUDr. Vladimír Donáth, CSc., MUDr. Silvia Laurincová
(2/2014, Main topic ) - Ocrelizumab, clinical aktivity and progression – long-term data
MUDr. Zbyšek Pavelek, PhD., doc. MUDr. Martin Vališ, Ph.D.
(3/2019, Pharmacotherapy ) - Longterm safety of Ocrelizumab in Multiple Sclerosis treatment
MUDr. Marek Peterka , MUDr. Pavel Potužník
(4/2020, Review articles ) - Biologics targeting CD20 molecule on B cells in the therapy of multiple sclerosis patients
Prof. RNDr. Jan Krejsek, CSc.
(6/2022, From the boundary of neurology ) - Shorter infusion of ocrelizumab in the treatment of multiple sclerosis
MUDr. Marek Peterka , MUDr. Pavel Potužník
(4/2021, Review articles ) - MR monitoring of activity of multiple sclerosis patients: conventional techniques and long-term MR monitoring of ocrelizumab therapy
prof. MUDr. Manuela Vaněčková, Ph.D.
(6/2019, From the boundary of neurology ) - Ocrelizumab v léčbě roztroušené sklerózy
Prof. MUDr. Eva Kubala Havrdová, CSc.
(4/2017, Pharmacotherapy ) - B‑ lymphocyte‑ targeted MS therapy: from theory to a decade of ocrelizumab in practice
MUDr. Dominika Šťastná, Ph.D., MUDr. Jana Seňavová, prof. MUDr. Dana Horáková, Ph.D.
(2/2024, Review articles ) - Does the development of new drugs for multiple sclerosis change the prognosis of the patient?
prof. MUDr. Eva Havrdová, CSc.
(3/2011, Review articles ) - Ocrelizumab and novel therapeutic goals in multiple sclerosis
MUDr. Radek Ampapa
(2/2020, Review articles )
- New therapy options for multiple sclerosis
Mgr. Ivana Pankuchová, MUDr. Ľubica Procházková, CSc., PharmDr. Adela Čorejová, PhD.
(4/2013, Current pharmacotherapy )